Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer February 19, 2026 Protara Therapeutics to Participate in Upcoming Investor Conferences February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium January 12, 2026 Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones January 7, 2026 Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support January 7, 2026 Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference January 5, 2026 Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations December 8, 2025 Protara Announces Closing of $75 Million Public Offering December 4, 2025 Protara Announces Pricing of $75 Million Public Offering Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 12 of 133 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer February 19, 2026 Protara Therapeutics to Participate in Upcoming Investor Conferences February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium January 12, 2026 Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones January 7, 2026 Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support January 7, 2026 Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference January 5, 2026 Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations December 8, 2025 Protara Announces Closing of $75 Million Public Offering December 4, 2025 Protara Announces Pricing of $75 Million Public Offering Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 12 of 133
April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
January 7, 2026 Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
January 5, 2026 Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
